Vol.:(0123456789) 1 3
Annals of Nuclear Medicine
https://doi.org/10.1007/s12149-020-01453-y
ORIGINAL ARTICLE
Relationships between amyloid levels, glucose metabolism,
morphologic changes in the brain and clinical status of patients
with Alzheimer’s disease
Tanyaluck Thientunyakit
1
· Chakmeedaj Sethanandha
1
· Weerasak Muangpaisan
2
· Orasa Chawalparit
1
·
Kuntarat Arunrungvichian
3
· Tossaporn Siriprapa
1
· Yudthaphon Vichianin
4
· Swatabdi Kamal
5
·
Chaiyawat Suppasilp
1
· Thonnapong Thongpraparn
1
· Rujaporn Chanachai
1
· Juri G. Gelovani
1,5
Received: 10 November 2019 / Accepted: 22 February 2020
© The Japanese Society of Nuclear Medicine 2020
Abstract
Objective The current study was conducted to improve the understanding of relationships between regional cortical amyloid
load, glucose metabolism, cortical morphology (volume), and severity of clinical symptoms in patients with AD, MCI, and
age-matched controls.
Methods To objectivize the radiological evaluation of patients with suspected AD, head-to-head multi-modality imaging
studies were conducted using MRI and PET/CT with [
18
F]FDG and [
18
F]AV45 for visualization and quantitation of brain
morphology, glucose metabolism, and amyloid levels, respectively. A total of 84 subjects was studied, including 33 patients
with AD, 31 patients with MCI, and 20 age-matched healthy controls (HC). A new quantitative index was calculated as a
ratio of regional SUV of [
18
F]AV45 (normalized to cerebellar cortex) over the corresponding regional SUV of [
18
F]FDG,
divided by the corresponding regional volume, measured from the co-registered MRI and normalized to the normal age-
matched control group (AV45/FDG/NVol index). Relationships between clinical scores (TMSE, ADAS) and AV45/FDG/
NVol indices for diferent structures of the brain in study groups were determined using linear regression analyses.
Results A signifcant direct linear correlation was observed between the AV45/FDG/NVol index and ADAS-Cog test score
and an inverse correlation with TMSE score at baseline and with the degree of changes in ADAS and TMSE scores assessed
one year later (disease progression). The observed correlations between AV45/FDG/NVol index and clinical scores were
higher than those with MRI-based cortical volumes, FDG SUV, or cerebellum-normalized AV45 SUV alone.
Conclusions Current study demonstrated that AV45/FDG/NVol index mapping of the brain is a novel quantitative molecular
imaging biomarker that correlates with clinical neurocognitive status and may facilitate more accurate diagnosis, staging, and
prognosis of AD. Additional larger scale clinical studies are required to further evaluate the efcacy of this new quantitative
index as a diagnostic and prognostic biomarker of AD as well as for the evaluation of safety and efcacy of novel agents
undergoing clinical trials for therapy of AD.
Keywords Alzheimer’s disease · Mild cognitive impairment · MRI · FDG · AV45 · Amyloid
Electronic supplementary material The online version of this
article (https://doi.org/10.1007/s12149-020-01453-y) contains
supplementary material, which is available to authorized users.
* Tanyaluck Thientunyakit
stanyalu@hotmail.com
1
Department of Radiology, Her Majesty’s Cardiac Center,
Division of Nuclear Medicine, Faculty of Medicine, Siriraj
Hospital, Building Fl.12th, 2 Wanglang Road Bangkoknoi,
Bangkok 10700, Thailand
2
Department of Preventive and Social Medicine, Siriraj
Hospital, Mahidol University, Bangkok, Thailand
3
Department of Pharmaceutical Chemistry, Faculty
of Pharmacy, Mahidol University, Bangkok, Thailand
4
Department of Radiological Technology, Faculty of Medical
Technology, Mahidol University, Bangkok, Thailand
5
Departments of Neurosurgery, Oncology, OBGYN,
Biomedical Engineering, School of Medicine, College
of Engineering, and Karmanos Cancer Institute, Wayne State
University, Detroit, MI, USA